NOVASEQ 6000 HIGH THROUGHPUT NEXT-GENERATION SEQUENCING (NGS) SYSTEM Solicitation ID/Procurement Identifier: FDA_192331210758 Ultimate Completion Date: Sat Aug 31 17:00:00 GMT 2024
The needed requirement is for quantitative next-generation sequencing done on cell free, whole plasma for a broad range of pathogens, to include DNA viruses, bacteria, fungi, molds, mycobacteria and protozoa. Cell free DNA of pathogens can be found in blood regardless of infection site and source.
Illumina - HiSeq X - PE 150 Cycle- Read length: 2 x 150 (Paired End) - Allocation: 56 lane(s) - Number of samples: 40 - Guaranteed output per sample: 140600 Mb - Guaranteed number of pass filter paired-end reads per sample: 933 million paired-end reads (466M reads in each direction) QC included (Qubit, Tapestation, qPCR) Sequencing Only Library PreparationLibrary type: Illumina - DNA (whole genome) - Number of libraries: 40 - Library prep kit: Kapa
SEQUENCING OF 120 MRNA SAMPLES USING ILLUMINA NEXT GENERATION SEQUENCING (NGS) Solicitation ID/Procurement Identifier: 75F40120P00352 Ultimate Completion Date: Thu Jul 08 17:00:00 GMT 2021
will allow GEN to process single and paired-end read data from Illumina-compatible libraries, and requires flexibility of flowcell selection to include flowcells that range from 100 million to at least 1 billion single-end reads in a single run.
NHLBI SEQUENCING CORE FACILITY REQUIRES ILLUMINA KITS AND REAGENTS IN ORDER TO CARRY OUT NEXT-GENERATION SEQUENCING ON ILLUMINA INSTRUMENTS FOR SUPPORTED INVESTIGATORS. Solicitation ID/Procurement Identifier: 75N92020D00022 Ultimate Completion Date: Tue Sep 02 17:00:00 GMT 2025
ILLUMINA INC:1107104 [20-003190] - TO PREPARE LIBRARIES FOR NEXT-GENERATION SEQUENCING OF 1056 PATIENT SAMPLES WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TO PREPARE LIBRARIES FOR NEXT-GENERATION SEQUENCI... Solicitation ID/Procurement Identifier: 75N92020D00022 Ultimate Completion Date: Tue Sep 02 17:00:00 GMT 2025
Because these tasks are undertaken daily in research laboratories, there has been an increasing demand for NGS services of FBR.
The objective of this sole source award is to procure Quantitative Next-Generation Sequencing Testing to be conducted on cell-free DNA in whole plasma for a broad range of pathogens, to include DNA viruses, bacteria, fungi, molds, mycobacteria and protozoa, to assist clinicians with rapidly diagnosing infectious diseases at NMCSD.